Literature DB >> 17954687

Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms.

Timothy D Starner1, Joshua D Shrout, Matthew R Parsek, Peter C Appelbaum, GunHee Kim.   

Abstract

Nontypeable Haemophilus influenzae (NTHi) commonly causes otitis media, chronic bronchitis in emphysema, and early airway infections in cystic fibrosis. Long-term, low-dose azithromycin has been shown to improve clinical outcomes in chronic lung diseases, although the mechanism of action remains unclear. The inhibition of bacterial biofilms by azithromycin has been postulated to be one mechanism mediating these effects. We hypothesized that subinhibitory concentrations of azithromycin would affect NTHi biofilm formation. Laboratory strains of NTHi expressing green fluorescent protein and azithromycin-resistant clinical isolates were grown in flow-cell and static-culture biofilm models. Using a range of concentrations of azithromycin and gentamicin, we measured the degree to which these antibiotics inhibited biofilm formation and persistence. Large biofilms formed over 2 to 4 days in a flow cell, displaying complex structures, including towers and channels. Subinhibitory concentrations of azithromycin significantly decreased biomass and maximal thickness in both forming and established NTHi biofilms. In contrast, subinhibitory concentrations of gentamicin had no effect on biofilm formation. Furthermore, established NTHi biofilms became resistant to gentamicin at concentrations far above the MIC. Biofilm formation of highly resistant clinical NTHi isolates (azithromycin MIC of > 64 microg/ml) was similarly decreased at subinhibitory azithromycin concentrations. Clinically obtainable azithromycin concentrations inhibited biofilms in all but the most highly resistant isolates. These data show that subinhibitory concentrations of azithromycin have antibiofilm properties, provide mechanistic insights, and supply an additional rationale for the use of azithromycin in chronic biofilm infections involving H. influenzae.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17954687      PMCID: PMC2223912          DOI: 10.1128/AAC.00607-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Deaths: final data for 2002.

Authors:  Kenneth D Kochanek; Sherry L Murphy; Robert N Anderson; Chester Scott
Journal:  Natl Vital Stat Rep       Date:  2004-10-12

2.  Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells.

Authors:  Masaharu Shinkai; Gregory H Foster; Bruce K Rubin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-08-05       Impact factor: 5.464

3.  Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.

Authors:  Lisa Saiman; Nicole Mayer-Hamblett; Preston Campbell; Bruce C Marshall
Journal:  Am J Respir Crit Care Med       Date:  2005-07-22       Impact factor: 21.405

4.  Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media.

Authors:  Luanne Hall-Stoodley; Fen Ze Hu; Armin Gieseke; Laura Nistico; Duc Nguyen; Jay Hayes; Michael Forbes; David P Greenberg; Bethany Dice; Amy Burrows; P Ashley Wackym; Paul Stoodley; J Christopher Post; Garth D Ehrlich; Joseph E Kerschner
Journal:  JAMA       Date:  2006-07-12       Impact factor: 56.272

5.  Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms.

Authors:  Richard J Gillis; Kimberly G White; Kyoung-Hee Choi; Victoria E Wagner; Herbert P Schweizer; Barbara H Iglewski
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis.

Authors:  Timothy D Starner; Niu Zhang; Gunhee Kim; Michael A Apicella; Paul B McCray
Journal:  Am J Respir Crit Care Med       Date:  2006-05-04       Impact factor: 21.405

7.  Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses.

Authors:  K M Olsen; G San Pedro; L P Gann; P O Gubbins; D M Halinski; G D Campbell
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia.

Authors:  Dimitris Panidis; Sophia L Markantonis; Eleni Boutzouka; Stylianos Karatzas; George Baltopoulos
Journal:  Chest       Date:  2005-08       Impact factor: 9.410

9.  Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-02.

Authors:  Susan M Schappert; Catharine W Burt
Journal:  Vital Health Stat 13       Date:  2006-02

10.  Cost-effectiveness considerations in otitis media treatment.

Authors:  G A Gates
Journal:  Otolaryngol Head Neck Surg       Date:  1996-04       Impact factor: 5.591

View more
  26 in total

Review 1.  Bacterial biofilms in the upper airway - evidence for role in pathology and implications for treatment of otitis media.

Authors:  Lauren O Bakaletz
Journal:  Paediatr Respir Rev       Date:  2012-05-27       Impact factor: 2.726

2.  Intercellular adhesion and biocide resistance in nontypeable Haemophilus influenzae biofilms.

Authors:  Era A Izano; Suhagi M Shah; Jeffrey B Kaplan
Journal:  Microb Pathog       Date:  2009-02-04       Impact factor: 3.738

Review 3.  Insights on persistent airway infection by non-typeable Haemophilus influenzae in chronic obstructive pulmonary disease.

Authors:  Christian P Ahearn; Mary C Gallo; Timothy F Murphy
Journal:  Pathog Dis       Date:  2017-06-01       Impact factor: 3.166

4.  Antimicrobial activity of antisense peptide-peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms.

Authors:  Taketo Otsuka; Aimee L Brauer; Charmaine Kirkham; Erin K Sully; Melinda M Pettigrew; Yong Kong; Bruce L Geller; Timothy F Murphy
Journal:  J Antimicrob Chemother       Date:  2016-09-28       Impact factor: 5.790

Review 5.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

6.  DNABII proteins play a central role in UPEC biofilm structure.

Authors:  Aishwarya Devaraj; Sheryl S Justice; Lauren O Bakaletz; Steven D Goodman
Journal:  Mol Microbiol       Date:  2015-04-16       Impact factor: 3.501

7.  Resistance of non-typeable Haemophilus influenzae biofilms is independent of biofilm size.

Authors:  Jennifer L Reimche; Daniel J Kirse; Amy S Whigham; W Edward Swords
Journal:  Pathog Dis       Date:  2016-12-11       Impact factor: 3.166

8.  Antibiofilm effects of azithromycin and erythromycin on Porphyromonas gingivalis.

Authors:  H Maezono; Y Noiri; Y Asahi; M Yamaguchi; R Yamamoto; N Izutani; H Azakami; S Ebisu
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

9.  Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization.

Authors:  Laura A Novotny; John D Clements; Lauren O Bakaletz
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

10.  Effects of azithromycin in combination with vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms.

Authors:  Elisabeth Presterl; Stefan Hajdu; Andrea M Lassnigg; Alexander M Hirschl; Johannes Holinka; Wolfgang Graninger
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.